Cytokinetics (NASDAQ:CYTK) Given New $53.00 Price Target at JPMorgan Chase & Co.
Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price target cut by JPMorgan Chase & Co. from $71.00 to $53.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of […]
Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price target cut by JPMorgan Chase & Co. from $71.00 to $53.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of […]
